Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 1/20 | 0.49 |
| ▸ | DRD2 | P14416 | 6/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | RAD52 | P43351 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | GFER | P55789 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | KHK | P50053 | 2/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8352129 | 0.85 | CHRNA7 (0.56) | CHRNA7DRD2GAARAD52KDM4E | |
| SCHEMBL4575666 | 0.85 | DRD2 (0.45) | DRD2SIGMAR1 | |
| SCHEMBL4576790 | 0.84 | DRD2 (0.47) | DRD2SIGMAR1 | |
| SCHEMBL4576540 | 0.83 | GAA (0.55) | CHRNA7GAARAD52KDM4EMAPT | |
| SCHEMBL4577137 | 0.82 | CHRNA7 (0.49) | CHRNA7DRD2GAARAD52KDM4E | |
| SCHEMBL2376462 | 0.76 | CHRNA7 (0.59) | CHRNA7DRD2GAARAD52KDM4E | |
| SCHEMBL29946558 | 0.75 | CHRNA7 (0.57) | CHRNA7DRD2GAARAD52KDM4E | |
| SCHEMBL29126309 | 0.75 | CHRNA7 (0.57) | CHRNA7DRD2GAARAD52KDM4E | |
| SCHEMBL1126080 | 0.74 | GAA (0.66) | CHRNA7DRD2GAARAD52KDM4E | |
| SCHEMBL30647354 | 0.74 | GAA (0.66) | CHRNA7DRD2GAARAD52KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080219996-A1 | Molecular Markers Associated with Bone Metastasis | NOVARTIS AG (CH) | 2008-09-11 | — | — | US | disclosed |
| EP-1931994-A2 | MOLECULAR MARKERS ASSOCIATED WITH BONE METASTASIS | Novartis AG (CH) | 2008-06-18 | — | — | EP | disclosed |
| US-20070135448-A1 | Use of cathepsin k inhibitors for treating of severe bone loss diseases | MISSBACH MARTIN | 2007-06-14 | — | — | US | disclosed |
| WO-2007038397-A2 | MOLECULAR MARKERS ASSOCIATED WITH BONE METASTASIS | NOVARTIS AG (CH) | 2007-04-05 | — | — | WO | disclosed |
| US-20060281714-A1 | Combinations of a cathepsin k inhibitor and a bisphosphonate in the treatment of bone metastasis, tumor growth and tumor-induced bone loss | ZIMMERMANN JOHANN | 2006-12-14 | — | — | US | disclosed |
| EP-1423121-B1 | CYSTEINE PROTEASE INHIBITORS WITH 2-CYANO-4-AMINO-PYRIMIDINE STRUCTURE AND CATHEPSIN K INHIBITORY ACTIVITY FOR THE TREATMENT OF INFLAMMATIONS AND OTHER DISEASES | NOVARTIS AG (CH) | 2006-11-15 | — | — | EP | disclosed |
| US-7112589-B2 | Cysteine protease inhibitors with 2-cyano-4-amino-pyrimidine structure and cathepsin k inhibitory activity for the treatment of inflammations and other diseases | NOVARTIS AG (CH) | 2006-09-26 | — | — | US | disclosed |
| EP-1686995-A1 | USE OF CATHEPSIN K INHIBITORS FOR TREATING OF SEVERE BONE LOSS DISEASES | Novartis AG (CH) | 2006-08-09 | — | — | EP | disclosed |
| EP-1651238-A1 | COMBINATIONS OF A CATHEPSIN K INHIBITOR AND A BISPHOPHONATE IN THE TREATMENT OF BONE METASTASIS, TUMOR GROWTH AND TUMOR-INDUCED BONE LOSS | Novartis AG (CH) | 2006-05-03 | — | — | EP | disclosed |
| US-20060074092-A1 | Cysteine protease inhibitors with 2-cyano-4-amino-pyrimidine structure and cathepsin K inhibitory activity for the treatment of inflammations and other diseases | ALTMANN EVA | 2006-04-06 | — | — | US | disclosed |
| WO-2005049028-A1 | USE OF CATHEPSIN K INHIBITORS IN SEVERE BONE LOSS DISEASES | NOVARTIS AG (CH) | 2005-06-02 | — | — | WO | disclosed |
| WO-2005014006-A1 | COMBINATIONS OF A CATHEPSIN K INHIBITOR AND A BISPHOPHONATE IN THE TREATMENT OF BONE METASTASIS, TUMOR GROWTH AND TUMOR-INDUCED BONE LOSS | NOVARTIS AG (CH) | 2005-02-17 | — | — | WO | disclosed |
| US-20040249153-A1 | Cysteine protease inhibitors with 2-cyano-4-amino-pyrimidine structure and cathepsin k inhibitory activity for the treatment of inflammations and other diseases | NOVARTIS AG (CH) | 2004-12-09 | — | — | US | disclosed |
| EP-1423121-A1 | CYSTEINE PROTEASE INHIBITORS WITH 2-CYANO-4-AMINO-PYRIMIDINE STRUCTURE AND CATHEPSIN K INHIBITORY ACTIVITY FOR THE TREATMENT OF INFLAMMATIONS AND OTHER DISEASES | Novartis AG (CH) | 2004-06-02 | — | — | EP | disclosed |
| WO-2003020278-A1 | CYSTEINE PROTEASE INHIBITORS WITH 2-CYANO-4-AMINO-PYRIMIDINE STRUCTURE AND CATHEPSIN K INHIBITORY ACTIVITY FOR THE TREATMENT OF INFLAMMATIONS AND OTHER DISEASES | NOVARTIS AG (CH) | 2003-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135448-A1 | Use of cathepsin k inhibitors for treating of severe bone loss diseases | CTSK, CTSB, CTSZ | CHRNA7 4836/4885DRD2 4681/4885GAA 37/4885 |
| US-20040249153-A1 | Cysteine protease inhibitors with 2-cyano-4-amino-pyrimidine structure and cathepsin k inhibitory activity for the treatment of inflammations and other diseases | CTSK, CTSS, CTSZ | CHRNA7 3894/4885DRD2 4763/4885GAA 381/4885 |
| US-20060281714-A1 | Combinations of a cathepsin k inhibitor and a bisphosphonate in the treatment of bone metastasis, tumor growth and tumor-induced bone loss | CTSK, CTSB, CTSZ | CHRNA7 4675/4885DRD2 4518/4885GAA 98/4885 |
| US-20080219996-A1 | Molecular Markers Associated with Bone Metastasis | BST2, BSG, CD44 | CHRNA7 4406/4885DRD2 4666/4885GAA 4498/4885 |
| US-20060074092-A1 | Cysteine protease inhibitors with 2-cyano-4-amino-pyrimidine structure and cathepsin K inhibitory activity for the treatment of inflammations and other diseases | CTSK, CTSS, CTSZ | CHRNA7 4044/4885DRD2 4752/4885GAA 378/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.